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Background: Mixed microbial infections of the respiratory tracts with P. aeruginosa and A. fumigatus capable of
producing biofilms are commonly found in cystic fibrosis patients. The primary objective of this study was to
develop an in vitro model for P. aeruginosa and A. fumigatus polymicrobial biofilm to study the efficacy of various
antimicrobial drugs alone and in combinations against biofilm-embedded cells. Simultaneous static cocultures of P.
aeruginosa and sporelings were used for the development of in vitro P. aeruginosa-A. fumigatus polymicrobial
biofilm in SD broth in 24-well cell culture plates at 35°C, and the biofilm formation was monitored microscopically
and spectrophotometrically. Using P. aeruginosa-A. fumigatus sporelings cocultures we examined the effects of
various antimicrobial drugs alone and in combination against polymicrobial biofilm by CFU and tetrazolium
reduction assays.
Results: In simultaneous static cocultures P. aeruginosa cells killed A. fumigatus conidia, whereas the bacterial cells
showed no substantial fungicidal effect on sporelings grown for 12 h or longer at 35°C. Monospecies cultures of P.
aeruginosa produced loosely adhered monomicrobial biofilm and addition of 10% bovine serum to the growth
medium inhibited the formation of monomicrobial biofilm by P. aeruginosa whereas it produced tightly adhered
polymicrobial biofilm in the presence of A. fumigatus mycelial growth. A. fumigatus produced firmly adherent
monomicrobial and polymicrobial biofilms. A comparison of CFU and MTT assays showed that the latter is
unsuitable for studying the effectiveness of antimicrobial treatment against polymicrobial biofilm. Tobramycin alone
and in combination with posaconazole was highly effective against monomicrobial and polymicrobial biofilms of P.
aeruginosa whereas cefepime alone and in combination with posaconazole showed excellent activity against
monomicrobial biofilm of P. aeruginosa but was less effective against polymicrobial biofilm. Monomicrobial and
polymicrobial biofilms of A. fumigatus showed similar susceptibility to posaconazole with and without the
antibacterial drug.
Conclusions: Simultaneous static coculture of A. fumigatus sporelings grown for 12 h or longer was superior to
ungerminated conidia with P. aeruginosa for the development of A. fumigatus-P. aeruginosa biofilm. P. aeruginosa-A.
fumigatus polymicrobial biofilm shows differential susceptibility to antimicrobial drugs whereas the susceptibility of
A. fumigatus to antimicrobial drugs was unchanged.* Correspondence: jvazquez@gru.edu
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Polymicrobial infection caused by multiple species of
microorganisms belonging to markedly different taxo-
nomic groups is a common occurrence in severely
immunocompromised patients [1-5] as well as in indi-
viduals suffering from persistent diabetic wounds [6-9],
chronic pulmonary obstructive disease [10-13], cystic fi-
brosis patients suffering from chronic infections [14-20]
and lung transplant recipients [21-23]. The microorgan-
isms more commonly isolated from mixed microbial in-
fections are pathogenic bacteria and fungi. A recent
retrospective study of the respiratory tract microbiology
of cystic fibrosis patients revealed that their airways were
colonized by multiple microorganisms, in particular
Pseudomonas aeruginosa (62% prevalence) in association
with Aspergillus species [24]. The epidemiology and clin-
ical significance of Aspergillus infection in cystic fibrosis
patients have been recently reviewed [25-27]. Among
the numerous Aspergillus isolates recovered from the re-
spiratory tracts of cystic fibrosis patients, A. fumigatus is
the most predominant species with a prevalence ranging
from 11% to 14% in the United States [28] and as high
as 60% to 78% in Europe [29,30], followed by A. terreus.
Although invasive aspergillosis can occur in persons
with cystic fibrosis, particularly after lung transplant-
ation, the most common complication of Aspergillus in-
fection is allergic bronchopulmonary aspergillosis
[31-34], a condition that causes the deterioration of lung
function associated with wheezing, shortness of breath,
cough and chest pain.
Given the high prevalence of P. aeruginosa and A.
fumigatus colonization of the airways of cystic fibrosis
patients, mixed microbial infection involving these mi-
croorganisms commonly occurs in the lungs [30,35,36]
producing monomicrobial and polymicrobial biofilms.
The biofilm-embedded cells are highly resistant to anti-
microbial drug therapy [37-40], difficult to eradicate and
often develop chronic infection that acts as a reservoir
causing serious life-threatening infection in individuals
with debilitated immune function. Several investigators
have recently studied A. fumigatus monomicrobial bio-
film using in vitro [40] and human bronchial epithelial
cell culture [38] models. The aerial or surface biofilm is
similar to the fungal ball often associated with aspergil-
loma in patients with lung cavitary lesions. The aerial
biofilm made up of fungal mycelia bound together by an
extracellular matrix composed of a variety of macromol-
ecules, including galactomannan, α1,3-glucan, monosac-
charides and polyols, melanin, proteins including major
antigens and hydrophobin molecules [41]. On the other
hand, Loussert et al. have recently [42] studied the com-
position of the mycelial extracellular matrix in vivo and
found to have less complex but similar composition. The
monomicrobial biofilm of A. fumigatus developed in 96-well cell culture plates and in human bronchial epithelial
cell culture were resistant to antimicrobial drugs [38,40].
Gene expression and proteomic studies by Bruns et al.
[43] showed that the 24-h biofilm expressed a greater
variety of genes whereas more mature older biofilm
expressed mainly specialized genes for the synthesis of
extracellular matrix and secondary metabolites such as
gliotoxin. Mowat et al [44] and Moree et al [45] have re-
cently investigated the in vitro interaction of A. fumiga-
tus with P. aeruginosa and demonstrated that A.
fumigatus biofilm formation is inhibited by small diffus-
ible molecules produced by P. aeruginosa whereas pre-
formed biofilm was only mildly affected. To date, very
little is known about the characteristics and antimicro-
bial drug susceptibility of mixed microbial biofilm pro-
duced by A. fumigatus and P. aeruginosa. In this paper
we describe the development and antimicrobial drug
susceptibility of a simple highly reliable in vitro polymi-
crobial biofilm model for A. fumigatus and P. aeruginosa
in 24-well cell culture plates using cocultures.
Methods
Microorganisms and culture conditions
A. fumigatus 53470 (AF53470), A. fumigatus ATCC
36607 (AF36607), P. aeruginosa 56402 (PA56402) and P.
aeruginosa ATCC27853 (PA27853) were used in this
study. AF53470 and PA56402 were clinical isolates ob-
tained from the Microbiology Laboratory of Henry Ford
Hospital in Detroit, Michigan, USA whereas AF36607
and PA27853 were commercially obtained from the
American Type Culture Collection, Manassas, VA
20110, USA.
The initial AF53470 and AF36607 cultures obtained from
the Microbiology Laboratory and American Type Cul-
ture Collection were subcultured on SD agar (Difco brand,
Becton Dickenson Diagnostics, Sparks, MD 21152, USA) for
checking the viability and purity, and subsequently stored
as conidial suspension in 25% glycerol at -80°C. Working
cultures were routinely maintained on SD agar plates at
4°C. AF53470 and AF36607 were highly susceptible to poly-
enes, triazoles and echinocandins, including amphotericin
B, voriconazole, posaconazole (MICs 1 μg/ml, 0.25 μg/ml,
0.062 μg/ml, respectively) and anidulafungin (MEC
0.031 μg/ml). For preparation of conidia, cultures were
grown on SD agar plates for 4 days at 35°C to produce large
amount of conidia. The SD agar containing the mycelial
growth was cut into small (5 mm2) pieces using a sterile
spatula, transferred to a 50-ml screw-capped conical culture
tube containing 25 ml sterile distilled water and vortexed
vigorously for 2 min to disperse the conidia from the conidi-
ophores. The resulting fungal suspension was filtered
through 8 layers of sterile cheese cloth to remove mycelial
and agar debris. The clarified conidial suspension thus ob-
tained was standardized by hemocytometer count and
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germinate in sterile distilled water at 4°C in the refrigerator
and remain viable for several months, thus if required the
same batch of conidial suspension can be used for several
experiments.
The initial PA56402 and PA27853 cultures obtained from
the Microbiology Laboratory and American Type Culture
Collection were subsequently subcultured on BHI agar
(Difco brand, Becton Dickenson Diagnostics, Sparks, MD
21152, USA) for the evaluation of purity and viability. The
colony purified isolates were stored in 25% glycerol at
-80°C. Working cultures were routinely grown on BHI agar,
stored at 4°C and subcultured at 37°C once a week to main-
tain viable stock cultures. PA56402 and PA27853 were
highly susceptible to a variety of antibacterial drugs such as
aminoglycosides, β-lactams and fluoroquinolones, including
tobramycin (MIC 0.125 μg/ml), cefepime (MIC ≤1 μg/ml)
and ciprofloxacin (MIC ≤ 0.25 μg/ml). Since PA56402 and
PA27853 grew well in SD broth we used this medium for
growing polymicrobial biofilms of A. fumigatus and P. aeru-
ginosa in mixed cultures. One ml aliquots of the overnight
cultures were centrifuged in a microcentrifuge at top speed
for 2 min and the pellets were washed 3 times (1 ml each)
with sterile distilled water, resuspended in 1 ml fresh SD
broth, standardized spectrophotometrically using a stand-
ard curve and subsequently used for various experiments.
The use of SD broth was particularly convenient for biofilm
development since it was commonly used to grow A. fumi-
gatus cultures.
Biofilm development
For the development of A. fumigatus and P. aeruginosa
monomicrobial and polymicrobial biofilm models, we
used Costar 24-well flat bottom cell culture plates [Cat.
no. 3526, Corning Incorporated, Corning, NY 14831,
USA]. Briefly, 1 × 106 A. fumigatus conidia prepared as
described above were incubated in 1 ml SD broth at
35°C in 24-well cell culture plates for 18 h, and allowed
them to germinate and grow producing a tightly adher-
ent monolayer of mycelial growth at the bottom of the
well. The surface mycelial growth was removed using a
sterile spatula and the spent growth medium was re-
moved by aspiration with a 1-ml micropipet. The adher-
ent mycelial layer was washed (3 times with sterile
distilled water, 1 ml each) using a 1-ml micropipet and
the wash fluid was completely removed by aspiration.
One ml SD broth was added to the mycelial growth
(18 h) and then inoculated with 1 × 106 P. aeruginosa
cells. The mixed culture was incubated at 35°C for either
24 h or 48 h for the development of a mixed microbial
culture producing polymicrobial biofilm. At the end of
the coculturing period, any remaining surface mycelial
growth was removed as previously described and the
mixed fungal-bacterial culture adhered to the bottom ofthe 24-well tissue culture plate was washed three times
with sterile distilled water (1 ml each). The adherent
layer of fungal and bacterial cells was scraped with a wet
sterile swab, resuspended in 1 ml of sterile distilled
water, vortexed vigorously for 30 seconds with 0.1 g ster-
ile glass beads to resuspend the cells and the biofilm
growth was determined by CFU and tetrazolium reduc-
tion assays. For CFU assay, the cell suspensions were
serially diluted 10 to 108 fold and 0.01 ml aliquots were
spotted on SD agar plates containing either ciprofloxacin
(50 μg/ml) or voriconazole (16 μg/ml) for selective fun-
gal and bacterial growth. The numbers of CFUs of A.
fumigatus and P. aeruginosa were determined after 24 h
growth at 35°C. For the development of monomicrobial
biofilms, A. fumigatus conidia and P. aeruginosa cells
were grown as monomicrobial cultures under identical
conditions and assayed for fungal and bacterial CFUs.
Photomicrography
For photomicrography the monomicrobial and polymi-
crobial biofilms of A. fumigatus and P. aeruginosa were
grown either on 22 mm sterile plastic microscopic
cover slips (Cat. no. 12547, Fisher Scientific Company,
Pittsburgh, PA) or in Costar 6-well flat bottom cell culture
plates [Cat. no. 3736, Corning Incorporated, Corning,
NY 14831, USA] in SD broth at 35°C. Briefly, the sterile
plastic cover slips were placed in a Costar 6-well cell
culture plate. Three ml aliquots of the A. fumigatus co-
nidial suspension containing 1 × 106 conidia/ml were
placed in each well completely covering the plastic cover
slip and the cell culture plate was incubated statically at
35°C for 18 h for A. fumigatus conidia to germinate and
form a monolayer of mycelial growth on the plastic
cover slips. The spent growth medium from each well
was removed and the cover slips containing the mycelial
growth were washed (3 times with sterile distilled water,
2 ml each) and inoculated with 3 ml of SD broth con-
taining 1 × 106 P. aeruginosa cells/ml. The mixed micro-
bial culture was incubated for 24 h at 35°C for the
development of A. fumigatus-P. aeruginosa polymicro-
bial biofilm. The plastic cover slips containing the mixed
microbial growth were washed (3 times with sterile dis-
tilled water, 2 ml each) and transferred to a clean Costar
6-well cell culture plate and stained with crystal violet
(0.04%) for 30 min at 35°C. The stained cover slips were
washed (4 times with sterile distilled water, 2 ml each)
and the excess water was drained. The cover slips were
briefly air-dried, mounted on a standard microscopic
slide using nail polish and the biofilms were photo-
graphed using a Nikon Microscope Camera System
equipped with SPOT image processing computer soft-
ware [46]. With the SPOT program, each Objective (10×
to 100×) of the microscope was previously calibrated
using a stage micrometer as described in the SPOT
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photomicrographs shown in Figure 1 were captured using
the 60X Objective providing a total magnification of 600X.
To develop monomicrobial biofilms of A. fumigatus and
P. aeruginosa, monomicrobial cultures of these organisms
were grown on plastic cover slips and processed identi-
cally. To study the kinetics of A. fumigatus monomicrobial
biofilm development from conidia, monomicrobial cul-
tures of A. fumigatus were grown in SD broth from a co-
nidial suspension for 0 h to 24 h in Costar 6-well cell
culture plates, washed, stained and photographed as de-
scribed above.C
A
Figure 1 Photomicrographic images and quantification of A. fumigatu
grown on plastic cover slips for 48 h at 35°C. B. Monomicrobial biofilm of P
biofilm formed in coculture by AF53470 sporelings and PA56402 grown on
using a Nikon Microscope Camera System equipped with SPOT image proc
Objective (10× to 100×) of the microscope was calibrated using a stage m
(Chapter 4, pages 76 and 77). The photomicrographs shown in Figure 1 we
600×. D. Quantification of 24-h and 48-h monomicrobial and polymicrobia
experiment by crystal violet binding assay was performed two times with e
ANOVA and paired Student’s t-test using GraphPad Prism 5.0. The vertical b
two independent experiments. The laboratory isolates AF36607 and PA278
plastic cover slips and Costar 6-well cell culture plates.Determination of the effects of antibiotics on biofilms
Monomicrobial and polymicrobial biofilms of A. fumiga-
tus and P. aeruginosa were developed in Costar 24-well
cell culture plates as previously described. The biofilms
were washed with distilled water (3 times, 1 ml each)
and incubated with the appropriate concentrations of
antimicrobial drug(s) for 24 h at 35°C. The drug-treated
biofilms were washed and the adherent cultures contain-
ing either fungal or bacterial or a mixed population of
fungal and bacterial cells were harvested by scraping the
bottom of the wells of the cell culture plates using sterile
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glass beads to disperse the cells, serially diluted 10 to
108 fold and 0.01 ml aliquots of the cell suspensions
were plated on ciprofloxacin (50 μg/ml) or voriconazole
(16 μg/ml) containing SD agar plates and incubated for
24 h at 35°C for selective growth. The number of CFUs
for each group was determined and plotted against the
drug concentration to assess the effectiveness of anti-
biotic treatment against biofilm bound cells.
One of the disadvantages of using CFU assay to deter-
mine the growth of filamentous fungi is the poor correl-
ation between biomass and CFU values. We therefore
performed a pilot experiment where 1 × 106 conidia
were germinated in 24-well cell culture plates in 1 ml
SD broth at 35°C form 0 h to 24 and the fungal growth
was determined by CFU assay. The number of CFUs ob-
tained was more or less correlated with the number of
conidia, germinated conidia and sporelings grown for up
to 12 h. But once the hyphae grew extensively producing
a mycelial biomass the correlation is usually reached a
plateau and remained unchanged because of the geom-
etry of the fully grown mycelial biomass and the pluripo-
tent nature of the vegetative hyphae. Thus, the CFU
assay for mature hyphae is at best an under estimation
of the total fungal biomass. Since our experiments were
designed to compare untreated drug-free controls to
drug-treated experimental groups, determination of the
absolute fungal biomass was not essential for demon-
strating comparative effect of the drug treatment.
Tetrazolium reduction assay
In addition to CFU assay, we evaluated the effects of
antimicrobial drugs on monomicrobial and polymicro-
bial biofilms of A. fumigatus and P. aeruginosa by the
tetrazolium reduction assay [47,48]. Briefly, monomicro-
bial and polymicrobial biofilms of A. fumigatus and P.
aeruginosa were washed three times with sterile distilled
water (1 ml each) and the excess water was removed by
aspiration with a 1 ml micropipet. The washed adherent
biofilm was overlaid with 1 ml fresh SD broth containing
100 mM 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide [MTT] and 0.2 mM menadione
and incubated at 35°C for 3 h for the reduction of the
tetrazolium compound. Under these conditions, the
lightly yellowish MTT will be reduced to an insoluble
blue tetrazolium salt accumulated within the mycelia. At
the end of the incubation period, the growth medium
containing MTT was removed and the biofilm was
washed three times (1 ml each) with sterile distilled
water, and intracellular insoluble tetrazolium salt was
dissolved in 1 ml 70% ethanol containing 0.1 N HCl for
30 min at 35°C. The amount of intracellular tetrazolium
salts was quantified spectrophotometrically by measur-
ing the absorbance of the solution at 570 nm. Theaccumulation of tetrazolium salt by the reduction of
MTT by cellular dehydrogenases is proportional to the
number of viable cells present in the biofilm. The effect-
iveness of the antimicrobial drug treatment was assessed
on the basis of diminished tetrazolium reduction.
Antimicrobial drugs
Pharmaceutical grade cefepime (Sagent Pharmaceuticals,
Schaumberg, IL, USA) and tobramycin pure powder
were obtained from the Henry Ford Hospital Pharmacy
and Sigma Chemical Company, St. Louis, USA, respect-
ively. Stock solutions (1 mg/ml) of the antibiotics were
prepared in sterile distilled water and stored as 0.25 ml
aliquots at -20°C. Voriconazole and posaconazole were
obtained from Pfizer Pharmaceuticals (New York,
NY, USA) and Schering-Plough Research Institute,
Kenilsworth, NJ, USA (now part of Merck), respectively.
The triazoles were dissolved in dimethylsulfoxide to ob-
tain a stock solution of 10 mg/ml and stored as 0.25-ml
aliquots at -20°C. The frozen stocks of the antimicrobial
drugs were thawed at room temperature and used within
24 h. Where it is applicable, comparable concentrations
of dimethylsulfoxide were used as control to examine its
effect on the growth of the organism.
Statistical analysis
The data were analyzed by Student’s t test, one-way and
two-way analysis of variance with Bonferroni’s Multiple
Comparison Test using Graphpad Prism Version 5.0 for
Windows (GraphPad Software, Inc., La Jolla, CA, USA).
A p value ≤0.05 was considered significant. Details of
each statistical test used are given in the corresponding
figure legend.
Results
Germinated conidia are more suitable for polymicrobial
biofilm formation
The initial attempt for developing an in vitro A. fumiga-
tus-P. aeruginosa polymicrobial biofilm model by simul-
taneous static coculturing of A. fumigatus conidia and P.
aeruginosa cells at a cell ratio of 1:1 resulted in the
complete killing of A. fumigatus cells. We therefore in-
vestigated the fungicidal effects of P. aeruginosa cell
densities ranging from 1 × 101 to 1 × 106 cells/ml on the
survival of 1 × 106 A. fumigatus conidia per ml after 24-
h simultaneous static coculturing. As shown in
Figure 2A, the fungicidal activity of P. aeruginosa against
A. fumigatus conidia was directly proportional to P. aer-
uginosa: A. fumigatus cell ratio. Ten and hundred
P. aeruginosa cells in 1 ml of SD broth containing 1 ×
106 conidia showed very little killing of A. fumigatus co-
nidia (P = 0.5456 and 0.0871, respectively), 1 × 103 and
1 × 104 P. aeruginosa cells showed moderate killing (P =
0.0002 and 0.0005, respectively) whereas 1 × 105 and 1 ×
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Figure 2 Effects of P. aeruginosa on A. fumigatus conidia (A) and sporelings (B) in cocultures. A. fumigatus conidia (A) and sporelings (B)
at a density of 1 × 106 cells/ml were incubated with P. aeruginosa cells ranging from 1 x 101-1 x 106 cells/ml in 1 ml SD broth at 35°C for 24 h. At
the end of the incubation the adherent microbial growth containing fungal and bacterial cells were washed 3 times with distilled water (1 ml
each) and the viability of the cells was determined by CFU assay. In all mixed cultures the P. aeruginosa CFUs were similar (≈1 × 1010 CFU/ml).
The experiment was performed at two different times with AF53470 and PA56402 using independently prepared conidial suspensions and
bacterial cultures, and one time with AF36607 and PA27853. Similar results were obtained for the clinical and the laboratory isolates. The vertical
bar on each data point represents the standard error of the mean for two independent experiments with AF53470 and PA56402. The data were
analyzed by one way ANOVA with Dunnett multiple comparison test where the control was compared with each of the experimental group
using GraphPad Prism 5.0.
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and 99.99% (P = 0.0003), respectively. In contrast, P. aer-
uginosa cell densities ranging from 1 × 101-1 × 106 cells/
ml did not affect the viability of A. fumigatus sporelings
grown from a conidial suspension for 12 h or longer and
provided more or less the same number of CFU/ml
[Figure 2B] after 24 h co-culturing. The lack of fungicidal
activity was not because of A. fumigatus inhibition of P.
aeruginosa growth since inoculation of sporelings with 1 ×
101 to 1 × 106 P. aeruginosa cells/ml provided approxi-
mately 1 × 1010 P. aeruginosa CFU/ml indicating that
growth of P. aeruginosa was not affected by the presence
of 1 × 106 A. fumigatus sporelings/ml. The P. aeruginosa
cells with faster growth rate reached stationary phase in
24 h in the presence of A. fumigatus sporelings and
formed a polymicrobial biofilm suggesting that a range of
P. aeruginosa cell densities could be used to develop a
polymicrobial biofilm with A. fumigatus sporelings.
Optimum conidial density for polymicrobial biofilm
formation
It was previously shown that A. fumigatus monomicro-
bial biofilm formation is a function of the conidial dens-
ity and production of optimum amount of biofilm was
dependent on the conidial density used [40]. We there-
fore examined the effect of conidial density on the devel-
opment of A. fumigatus-P. aeruginosa polymicrobial
biofilm. As shown in Figure 3A, a plot of A. fumigatus
conidial density ranging from 1 × 102 to 1 × 107conidia/ml used for the mycelial growth against the bio-
film associated CFUs obtained for A. fumigatus and P.
aeruginosa showed that a seeding density of 1 × 106 co-
nidia/ml provided the best yield of mixed microbial bio-
film producing the most number of CFUs for both
organisms. Although 1 × 107conidia/ml produced the
highest number of CFUs for A. fumigatus, the number
of P. aeruginosa CFUs obtained was lower than that ob-
tained when 1 × 106conidia/ml was used. Among three
different conidial densities (1 × 104, 1 × 105 and 1 × 106
cells/ml) Mowat et al. used, 1 × 105 conidia/ml pro-
duced the best A. fumigatus biofilm in a 96-well microti-
ter plate [36]. The difference may be due to the
difference in the surface area of the wells of 96-well and
24-well cell culture plates, or the growth media
(RPMI1640 vs. SD broth) used or the assays (tetrazolium
reduction vs. CFU determination) used to measure the
biofilm growth.
Effects of various growth media with and without bovine
serum on biofilm development
One of the primary objectives of this experiment was to
identify a simple growth medium in which both A. fu-
migatus and P. aeruginosa would grow well and me-
thodology for the formation of monomicrobial and
polymicrobial biofilms will be simple for antimicrobial
drug susceptibility testing of biofilms. The need to iden-
tify a suitable growth medium for P. aeruginosa biofilm
formation was important because in general it produced



































Figure 3 Effects of cell density and growth medium on biofilm formation. A. Effect of conidial density on A. fumigatus-P. aeruginosa
polymicrobial biofilm formation. One ml aliquots of AF53470 conidial suspension containing 1 × 102 - 1 × 107 conidia/ml were incubated in 24-
well cell culture plates in duplicates at 35°C in SD broth for 18 h, washed and then inoculated with 1 × 106 PA56402 cells in 1 ml SD broth and
further incubated for 24 h for the development of A. fumigatus-P. aeruginosa polymicrobial biofilm. The biofilm was washed and the embedded
cells were resuspended in 1 ml sterile water and assayed for A. fumigatus and P. aeruginosa by CFU counts. The experiment was performed at
two different times using independently prepared conidial suspensions and bacterial cultures and the vertical bar on each data point on the
graph represents the standard error of the mean. B. P. aeruginosa monomicrobial biofilm formation in various growth media with and without
bovine serum. One ml aliquots of growth media containing 1 × 106 P. aeruginosa cells were incubated in quadruplicates in 24-well cell culture
plates with and without 10% bovine serum for 24 h at 35°C for biofilm formation. The adherent monomicrobial biofilm was washed (3 times),
resuspended in 1 ml sterile distilled water and the biofilm growth was assessed by CFU assay. The experiment was performed two different times
with PA56402 using independently prepared bacterial cultures, and one time with PA27853. Both sets of isolates provided similar results. The data
were analyzed by paired Student’s t test using GraphPad prism 5.0. The vertical bar on each histogram denotes standard error of the mean for
two independent experiments using PA56402. Legends: SD, Sabouraud’s dextrose broth; SD-BS, Sabouraud’s dextrose broth with 10% bovine
serum; BHI, Brain Heart Infusion broth; BHI-BS Brain Heart Infusion broth with 10% bovine serum; RPMI, RPMI640; RPMI-BS, RPMI1640 with 10%
bovine serum.
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polystyrene culture plates. Since pretreatment of certain
plastics with bovine serum preconditions their surfaces
for better cell attachment and biofilm production
[49,50], we examined the effect of 10% bovine serum in
the growth medium on the formation of P. aeruginosa
biofilm. All three media we used were able to support
the formation of P. aeruginosa biofilm to varying degree
where BHI being the best medium followed by SD broth
and RPMI1640 (Figure 3B). A comparison of the CFUs
obtained for various media with and without bovine
serum showed that the presence of 10% bovine serum
inhibited P. aeruginosa monomicrobial biofilm forma-
tion by 27% in SD (P = 0.0509), 95% in BHI (P = 0.00016)
and 89% in RPMI1640 (P = 0.00078) suggesting that bo-
vine serum has a negative effect on P. aeruginosa biofilm
formation in Costar cell culture plates. Thus, in our sub-
sequent experiments, we used SD broth for the develop-
ment of monomicrobial and polymicrobial biofilms of A.
fumigatus and P. aeruginosa. The fact that A. fumigatus
produces excellent monomicrobial biofilm in SD broth
made it a highly suitable medium for the production of
polymicrobial biofilms.Biofilm images and quantification
Figure 1 shows photomicrographic images of 24-h mono-
microbial biofilms of A. fumigatus (A), P. aeruginosa (B)
and A. fumigatus-P. aeruginosa polymicrobial biofilm (C)
grown on plastic cover slips. A. fumigatus produced an ex-
tensive firmly adherent mycelial growth on the plastic cover
slips and in any one microscopic field only a few hyphal fil-
aments were in focus suggesting that as the hyphae grew
they branched extensively forming a network of mycelial
growth producing a three dimensional structure. The
monomicrobial culture of P. aeruginosa growing on plastic
cover slips formed a loosely adhered biofilm and gentle
washing did not affect its stability on the plastic cover slips.
On the other hand, washing of the biofilm with agitation
randomly dislodged the cells from the plastic cover slips.
The mixed microbial biofilm of A. fumigatus and P. aerugi-
nosa showed a hazy background in which numerous P. aer-
uginosa cells were embedded in a mesh-like material. In the
same planar field where the bacterial cells were in clear
view the fungal hyphae were out of focus and numerous
bacterial cells were seen adhered to the fungal hyphae using
as scaffolding forming a mixed community of microbial
growth.
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the duration of culturing, we investigated the effect of
incubation time on the production of monomicrobial
and polymicrobial biofilms of A. fumigatus and P. aeru-
ginosa. A comparison of the amounts of crystal violet
bound by 24-h and 48-h monomicrobial and polymicro-
bial biofilms of A. fumigatus and P. aeruginosa showed
that the 48 h biofilm mass was increased by 57.7%,
61.7% and 94.5% (P ≤ 0.0044) for A. fumigatus, A.
fumigatus-P. aeruginosa and P. aeruginosa biofilms, re-
spectively (Figure 1D). However, no significant difference
in CFUs was obtained for 24-h and 48-h biofilms (data
not shown) suggesting that CFU determination is less
than suitable for the determination fungal growth in
more mature biofilms (e.g., 48 h biofilm). However, the
24 h and 48 h polymicrobial biofilms of A. fumigatus-P.
aeruginosa were almost equally susceptible to antimicro-








































Figure 4 Effects of voriconazole alone and in combination with cefep
aeruginosa polymicrobial biofilms as determined by CFU (A) and MTT
and the effectiveness of antimicrobial drug(s) treatment was assessed by th
two different times with the clinical isolates AF53470 and PA56402 using in
one time with the laboratory isolates AF36607 and PA27853. Similar results
two-way ANOVA with Bonferroni post test analysis by comparing each trea
Prism 5.0. The vertical bar on each data point denotes standard error of the
Legends: AF, A. fumigatus monomicrobial biofilm; AF + PA, A. fumigatus-PDrug susceptibility studies
To examine the suitability of our in vitro biofilm model
for functional studies, we investigated the effectiveness
of several antimicrobial drugs individually and in two-
drug combinations against monomicrobial and polymi-
crobial biofilms of P. aeruginosa and A. fumigatus using
CFU and tetrazolium reduction assays. Figure 4A shows
representative results for voriconazole alone and in com-
bination with cefepime on A. fumigatus monomicrobial
and A. fumigatus-P. aeruginosa polymicrobial biofilms as
determined by the CFU assay. Voriconazole at a concen-
tration of 32 μg/ml reduced the CFU of monomicrobial
and polymicrobial biofilms by approximately 1.5 logs
suggesting that A. fumigatus cells embedded in monomi-
crobial and polymicrobial extracellular matrix were simi-
larly susceptible (P = 0.3681) to the triazole voriconazole.
On the other hand, voriconazole in combination with












ime against A. fumigatus monomicrobial and A. fumigatus-P.
(B) assays. The biofilms were developed in 24-well cell culture plates
e reduction of CFUs and A570 values. Each experiment was performed
dependently prepared conidial suspensions and bacterial cultures, and
were obtained for both set of isolates. The data were analyzed by
tment group to the other for statistical significance using Graphpad
mean for two experiments performed with AF53470 and PA56402.
. aeruginosa polymicrobial biofilm; VCZ, voriconazole; CEF, cefepime.
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http://www.biomedcentral.com/1471-2180/14/53against monomicrobial and polymicrobial biofilms (0.5
to 1 logs CFU reduction at 32 μg/ml) compared to vori-
conazole alone but showed no statistical significance
(P = 0.5724).
Figure 4B shows the effectiveness of voriconazole
alone and in combination with cefepime against A. fumi-
gatus monomicrobial and A. fumigatus-P. aeruginosa
polymicrobial biofilms as determined by MTT assay. A
comparison of the A570 values obtained for monomicro-
bial and polymicrobial biofilms as a function of vorico-
nazole concentration showed that the polymicrobial
biofilm is less susceptible to the fungicidal activity of the
antifungal drug (P < 0.01). Similarly, voriconazole in
combination with cefepime was less active against poly-
microbial biofilm compared to the activity against
monomicrobial biofilm (P < 0.01). This finding is con-
trary to what was obtained in the CFU assay where both
monomicrobial and polymicrobial biofilms of A. fumiga-
tus was almost equally susceptible to voriconazole with
and without cefepime. Thus, the apparent resistance of
A. fumigatus in polymicrobial biofilm to voriconazole
may be an artifact of the MTT assay due to the presence
of P. aeruginosa cells not susceptible to voriconazole but
actively contributing to tetrazolium reduction in the
polymicrobial biofilms. In support of this suggestion it
was noted that a comparison of the effect of voricona-
zole alone and in combination with cefepime against
monomicrobial biofilm is very similar (P > 0.05). Simi-
larly, the effect of voriconazole alone and in combination
with cefepime against A. fumigatus-P. aeruginosa biofilm
is almost identical (P > 0.05) showing no significant dif-
ference. Thus, since there is no suitable way of separat-
ing the fungal and the bacterial contributions to the
tetrazolium reduction the MTT assay is unsuitable for
studying the bioactivity of voriconazole against A. fumi-
gatus biofilm.
Figure 5 shows the effects of cefepime and posacona-
zole individually and in combination on monomicrobial
and polymicrobial biofilms of P. aeruginosa and A. fumi-
gatus. A comparison of the susceptibilities of A. fumiga-
tus monomicrobial and A. fumigatus-P. aeruginosa
polymicrobial biofilms to posaconazole with and without
cefepime (Panel A) provided 1 to 1.5 logs CFU reduction
at a drug(s) concentration of 64 μg/ml and showed no
significant difference (P > 0.05). In contrast, a compari-
son of the effects of cefepime on P. aeruginosa monomi-
crobial (≈4.5 logs CFU reduction at a 64 μg/ml) and P.
aeruginosa-A. fumigatus polymicrobial (≈1.5 logs CFU
reduction at 64 μg/ml) biofilms (Panel B) showed that
the polymicrobial biofilm is significantly less susceptible
to cefepime (P < 0.0001). Similarly, a comparison of the
effects of combination of cefepime with posaconazole on
monomicrobial biofilm of P. aeruginosa (≈4 logs CFU
reduction at 64 μg/ml) with that obtained forpolymicrobial biofilm (≈1.5 logs CFU reduction at
64 μg/ml) showed that polymicrobial biofilm is also sig-
nificantly less susceptible to the combination of drugs
(P = 0.0013). However, a comparison of the susceptibility
of P. aeruginosa monomicrobial biofilm to cefepime
alone (≈4.5 logs CFU reduction at a 64 μg/ml) and cefe-
pime plus posaconazole (≈4 logs CFU reduction at
64 μg/ml) showed no significant difference (P = 0.4234)
indicating that posaconazole has no detectable effect on
the antibacterial activity of cefepime. Similarly, a com-
parison of the effect of cefepime on polymicrobial bio-
film (≈1.5 logs CFU reduction at 64 μg/ml) with that of
the combination of cefepime and posaconazole (≈1.5
logs CFU reduction at 64 μg/ml) showed that the poly-
microbial biofilm was almost equally susceptible (P =
0.4057) to the drug combination suggesting that the
presence of posaconazole in the combination did not
affect bioactivity of cefepime against polymicrobial
biofilm.
Since cefepime alone and in combination with posaco-
nazole showed differential activity against P. aeruginosa
monomicrobial and P. aeruginosa-A. fumigatus polymi-
crobial biofilms, we investigated the effect of tobramycin
alone and in two-drug combination with posaconazole.
As shown in Figure 6A, posaconazole with and without
tobramycin was almost equally effective against both
monomicrobial and polymicrobial biofilms with approxi-
mately 2 to 2.5 logs CFU reduction at a drug concentra-
tion of 64 μg/ml (P > 0.05). Similarly, Figure 6B shows
the effect of tobramycin alone and in combination with
posaconazole against P. aeruginosa monomicrobial and
P. aeruginosa-A. fumigatus polymicrobial biofilms.
Tobramycin with and without posaconazole were equally
active against the P. aeruginosa monomicrobial and P.
aeruginosa-A. fumigatus polymicrobial biofilms with ap-
proximately 5-6 logs CFU reduction at a drug concen-
tration of 64 μg/ml (P > 0.05). These results also show
that tobramycin and posaconazole has no in vitro drug-
to-drug interaction to reduce the bioactivity of the other
drug. The excellent activity of tobramycin against mono-
microbial and polymicrobial biofilms is in sharp contrast
to the differential effects of cefepime alone and in
combination with posaconazole against monomicrobial
and polymicrobial biofilms of A. fumigatus and P.
aeruginosa.
Discussion
P. aeruginosa is known to produce an array of small
molecules possessing antimicrobial activity by direct or
indirect interaction with cells. So one of the intriguing
questions is why A. fumigatus hyphae are refractory to
the fungicidal effect of P. aeruginosa whereas conidia
and sporelings are completely killed. Several reasons
could be mentioned for the poor susceptibility of A.

























































Figure 5 Biofilm inhibition by posaconazole and cefepime. A. Effects of posaconazole alone and in combination with cefepime against A.
fumigatus monomicrobial and A. fumigatus-P. aeruginosa polymicrobial biofilms. B. Effects of cefepime alone and in combination with
posaconazole against P. aeruginosa monomicrobial and P. aeruginosa-A. fumigatus polymicrobial biofilms. Each experiment was performed two
different times with the clinical isolates AF53470 and PA57402 using independently prepared conidial suspensions and bacterial cultures, and one
time with the laboratory isolates AF36607 and PA27853. Both clinical and laboratory isolates provided similar results. The data were analyzed by
one-way and two-way ANOVA with Bonferroni’s multiple comparison test where each set of data is compared with all the other sets of data as
well as by paired two-tailed Student’s t-test using Graphpad Prism 5.0. The vertical bar on each data point denotes standard error of the mean for
two independent experiments performed with the clinical isolates. Legends: AF, A. fumigatus monomicrobial biofilm; PA, P. aeruginosa
monomicrobial biofilm; PA + AF and AF + PA, polymicrobial biofilm; CEF, cefepime; PCZ, posaconazole.
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http://www.biomedcentral.com/1471-2180/14/53fumigatus hyphae to the inhibitory effect of P. aerugi-
nosa in mixed cultures: (1) Gliotoxin is a cytotoxic com-
pound with antibacterial activity produced by A.
fumigatus. The synthesis of this mycotoxin molecule is
upregulated during mycelial growth in A. fumigatus, in
particular during biofilm formation. So the increased
level of gliotoxin during biofilm formation could inhibit
P. aeruginosa growth or retards its ability to kill A. fumi-
gatus. (2) It is generally known that metabolic activity of
the cells is essential for P. aeruginosa virulence factors
to be effective eliciting its inhibitory action. Germinating
conidia and young sporelings are more or less uniformly
metabolically active whereas in more mature hyphae
metabolic activity is restricted to the apical regions ofthe filaments where hyphal extension takes place, al-
though any part of growing hyphae is capable of regen-
eration (pluripotent) producing an actively growing
fungal colony. Thus, the metabolically quiescent vegeta-
tive mycelia are less susceptible to the cytotoxic mole-
cules produced by P. aeruginosa. (3) The cell wall
chemistry of the mature hyphae is different from that of
the young hyphae and the cell wall of matured hyphae
may have restricted permeability to P. aeruginosa pro-
duced toxic molecules.
P. aeruginosa is a well known biofilm producer both in
the laboratory and in clinical settings, especially in
chronic infections [51-59]. One of the hallmarks of P.
aeruginosa biofilm is its profound tolerance for




























































Figure 6 Biofilm inhibition by posaconazole and tobramycin. A. Effects of posaconazole alone and in combination with tobramycin against
A. fumigatus monomicrobial and A. fumigatus-P. aeruginosa polymicrobial biofilms. B. Effects of tobramycin alone and in combination with
posaconazole against P. aeruginosa monomicrobial and P. aeruginosa-A. fumigatus polymicrobial biofilms. Each experiment was performed two
different times with the clinical isolates AF53470 and PA57402 using independently prepared conidial suspensions and bacterial cultures, and one
time with the laboratory isolates AF36607 and PA27853. Both clinical and laboratory isolates provided similar results. The data were analyzed by
one-way and two-way ANOVA with Bonferroni’s multiple comparison test where each set of data is compared with all the other sets of data as
well as by paired two-tailed Student’s t-test using Graphpad Prism 5.0. The vertical bar on each data point denotes standard error of the mean for
two independent experiments performed with the clinical isolates. Legends: AF, A. fumigatus monomicrobial biofilm; PA, P. aeruginosa monomi-
crobial biofilm; AF + PA and PA + AF, polymicrobial biofilm; PCZ, posaconazole; TOB, tobramycin.
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individual cells of the biofilm community are highly drug
susceptible in planktonic cultures [38,40,42,60,61].
Nearly four decades of research has provided a wealth of
valuable information on the genesis, architecture, chem-
ical composition and the drug susceptibility of P. aerugi-
nosa biofilm [62,63]. In contrast, currently we know very
little about A. fumigatus biofilm and the first report on
A. fumigatus monomicrobial biofilm was published by
Mowat et al. [40,60] in 2007. These investigators de-
scribed that A. fumigatus forms an extensive net work of
hyphae producing a multicellular community firmly at-
tached to a solid substrate, and the adherent mycelial
growth was encased in an extracellular matrix thatresembles a biofilm microbial community. In addition,
these investigators described that the extracellular
matrix bound adherent fungal cells were highly resistant
to antifungal drug treatment [40,60,64] compared to
their free-floating counter parts.
The high prevalence [65,66] of P. aeruginosa and A.
fumigatus in CF patients suffering from persistent lung
infection provides a highly suitable ecological niche for
the production of mixed microbial biofilm. The charac-
teristics of polymicrobial biofilms produced by these or-
ganisms in mixed microbial cultures are largely
unknown. Thus, the primary objective of our study was
to develop a simple reliable easy to perform procedure
for the development of a stably adhered polymicrobial
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http://www.biomedcentral.com/1471-2180/14/53biofilm of A. fumigatus and P. aeruginosa using mixed
microbial culture of these organisms.
We examined several types of multi-well cell culture
plates (6-well to 96-well) and growth media for the de-
velopment of A. fumigatus-P. aeruginosa polymicrobial
biofilm in cocultures. Although the 96-well cell culture
plate would give a large number of replications for anti-
microbial susceptibility studies, the wells in 96-well cell
culture plates were found to be too small to prevent
cross-contamination between wells by the surface
growth of A. fumigatus. In contrast, the 6-well and 12-
well cell culture plates were found to be too big and
comparatively large volumes of medium were needed for
the development of biofilms and provided limited num-
ber of replications for drug susceptibility studies. In our
experience, Costar 24-well cell culture plates were ideal
for the development of in vitro monomicrobial and
polymicrobial biofilms of A. fumigatus and P. aeruginosa
and provided sufficient number of wells for replications.
The large deep wells were adequately separated for
multiple manipulations of the biofilm without cross-
contamination between wells. In SD broth the 24-h and
48-h mixed microbial cultures of A. fumigatus and P.
aeruginosa produced polymicrobial biofilms at 35°C. Al-
though the biofilm mass was significantly higher in 48 h
biofilm, there was no significant difference for the CFU
values obtained for the 24-h and 48-h cocultures. There-
fore, we would suggest that 24 h growth of the mixed
microbial culture will be sufficient to produce a func-
tional A. fumigatus-P. aeruginosa polymicrobial biofilm
for antimicrobial drug susceptibility studies.
The tetrazolium reduction assay has been used by sev-
eral investigators in the past to examine the viability of a
variety of eukaryotic cells ranging from mammalian to
fungal cells, including members of the genus Aspergillus
[48,67-71]. Therefore, we investigated the feasibility of
using methyltetrazolium (MTT) assay for monitoring
the viability of A. fumigatus cells after coculturing with
P. aeruginosa in mixed microbial biofilms. The MTT
assay has been used in our laboratory [68] previously,
found to be convenient and highly sensitive for monitor-
ing the viability of A. fumigatus cells, in particular after
exposure to antifungal drugs. Similarly, we found in the
current series of experiments that the MTT assay was
very useful for monitoring the viability of A. fumigatus
cells in monospecies cultures after 24 h and 48 h
growth. However, in the mixed species cultures where A.
fumigatus and P. aeruginosa were grown together in co-
cultures although the assay was highly sensitive and easy
to perform, it was found to be difficult to distinguish the
contribution made by the bacterial and fungal cells to-
wards the reduction of the MTT compound. Therefore,
we used only the CFU assay to monitor the growth of A.
fumigatus cells in mixed microbial biofilms and for drugsusceptibility studies. Apart from the inconvenience, the
main disadvantages of using the CFU assay for deter-
mining the viability of A. fumigatus cells are the under
estimation of CFUs due to clumping of hyphae and that
the bacteria-treated fungal cells can be inhibited from
growing without being killed. Since the end point of
CFU assay is the formation of fungal colonies by individ-
ual cells, growth inhibition without killing would go un-
detected. Nonetheless, the fact that we washed the
treated cells extensively with sterile distilled water makes
it unlikely that in our experiments the fungal cells were
only inhibited by the bacterial cells without killing them.
Our results show that the monomicrobial and the
polymicrobial biofilms of A. fumigatus and A. fumigatus-
P. aeruginosa were almost equally susceptible to antifun-
gal drugs such as voriconazole and posaconazole. The
main reasons for the biofilm to exhibit drug resistance/
tolerance are (1) biofilm specific upregulation of efflux
proteins (2) the presence of an extracellular matrix and
(3) the presence of persistor cells that are inherently
drug resistant/tolerant due to their low metabolic rate. It
is likely that there is no differential upregulation of ef-
flux proteins in monomicrobial and polymicrobial bio-
films of A. fumigatus and A. fumigatus-P. aeruginosa.
Similarly, although it is possible that the extracellular
matrix produced by monomicrobial and polymicrobial
biofilms of A. fumigatus and A. fumigatus-P. aeruginosa
mixed culture is different, the difference in the perme-
ability characteristics of monomicrobial and polymicro-
bial biofilm produced extracellular matrices are not
sufficient enough to show any reduction in drug pene-
tration. Since the growth characteristics and the biology
of A. fumigatus is vastly different from other unicellular
organisms such as bacteria and pathogenic yeasts, the
presence of persistor cells inherently resistant to anti-
microbial drug is highly unlikely. Together, these points
suggest that although differential antifungal drug suscep-
tibility for A. fumigatus monomicrobial and polymicro-
bial biofilms was expected, the lack of such response is
not entirely surprising.
In contrast, our antimicrobial drug susceptibility stud-
ies showed that polymicrobial biofilm associated P. aeru-
ginosa cells are less susceptible to cefepime in
comparison to their monomicrobial counterparts. The
extracellular matrix of P. aeruginosa biofilm is composed
of proteins, polysaccharides, in particular alginate, and
eDNA whereas that of A. fumigatus biofilm is made up
of galactomannan, alpha-1,3 glucans, monosaccharides
and polyols, pigments, proteins and eDNA. The most
plausible explanation for the reduced susceptibility of
polymicrobial biofilm embedded P. aeruginosa is the dif-
ference in the make up of the extracellular matrix of
monomicrobial (P. aeruginosa) and mixed microbial (P.
aeruginosa-A. fumigatus) biofilms. The polymicrobial
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different from that of the monomicrobial extracellular
matrix preventing adequate access to the biofilm embed-
ded cells.Conclusions
The high prevalence of P. aeruginosa and A. fumigatus
colonization of the airways of CF patients results in
mixed microbial chronic infections. The polymicrobial
CF patient airway infection with P. aeruginosa and A.
fumigatus produces mixed microbial biofilm with struc-
tural and functional characteristics different from those
of monomicrobial biofilms. The monomicrobial extracel-
lular matrix embedded bacterial and fungal cells are
highly resistant to antimicrobial drug therapy. Although
the formation of mixed microbial biofilm is considered
to be a serious clinical problem in CF patients as well as
in other patient groups prone to airway infection with P.
aeruginosa and A. fumigatus, we know very little about
the antibiotic susceptibility of P. aeruginosa-A. fumigatus
polymicrobial biofilm. We therefore investigated the
feasibility of developing an in vitro polymicrobial biofilm
model using simultaneous static cocultures of A. fumiga-
tus and P. aeruginosa for studying drug susceptibility.
Simultaneous coculturing of A. fumigatus conidia with
P. aeruginosa resulted in the complete killing of the fun-
gus whereas A. fumigatus sporelings grown for 12 h or
longer were recalcitrant to the fungicidal activity of P.
aeruginosa and the young hyphae were highly suitable
for producing sustainable polymicrobial biofilm with P.
aeruginosa in cocultures. Using this in vitro model we
studied the effects of cefepime and tobramycin alone
and combination with posaconazole on monomicrobial
and polymicrobial biofilms of P. aeruginosa and A. fumi-
gatus. Our results show that P. aeruginosa cells associ-
ated with polymicrobial biofilm were less susceptible to
cefepime (but not to tobramycin) compared to those of
monomicrobial biofilm. On the other hand, A. fumigatus
showed similar antifungal drug susceptibility in mono-
microbial and polymicrobial biofilms.
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